MedWatch

Biogen's EU setback highlights importance of research, says Alzheimer's organization

The expected EU rejection of Biogen's Alzheimer's drug has put a focus on the importance of dementia research, and may incentivize other pharmaceutical companies to throw their hats into the ring, says the head of the Danish non-profit Alzheimer's organization, Alzheimerforeningen. A professor of dementia also predicts a future need for earlier disease tracing, should Aduhelm be approved in Denmark.

Nis Peter Nissen, head of Danish non-profit organization Alzheimerforeningen | Photo: Mathias Christensen/Politiken/Ritzau Scanpix

Although the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) giving the company's Alzheimer's drug Aduhelm (aducanumab) the thumbs-down in a trend vote on Wednesday was a spanner in the works for Biogen, there might still be a silver lining for the company.

The increased media coverage caused by the rejection – which in all likelihood also means a formal rejection is headed Aduhelm's way when the CHMP sits for its December meeting – has put the dementia area and its success criteria back into the spotlight.

Read the whole article

Get 14 days free access.
No credit card required.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

"Real world" patient data documents the long-term effects of ALK vaccines

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers. 

Further reading

Related articles

Latest news

See all jobs